|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 04, 2018 ) Browse 105 Market Data Tables and 37 Figures spread through 170 Pages and in-depth TOC on "Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022"
https://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html
Early buyers will receive 10% customization on this reports
Based on technology, the polymerase chain reaction (PCR) segment accounted for the largest share of the market in 2016
On the basis of technology, the companion diagnostics market is broadly segmented into polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), next-generation sequencing (NGS), and other technologies. In 2016, the polymerase chain reaction (PCR) segment accounted for the largest share of this market and the next-generation sequencing (NGS) segment is expected to register the highest CAGR during the forecast period. The large share of the PCR segment is attributed to its ease of use and to the fact that it does not require many samples for biomarker identification.
Based on indication of companion diagnostics market, the oncology segment held the largest market share in 2016
Based on the indication, the global companion diagnostics market is divided into oncology, infectious diseases, neurology, and other indications. The oncology segment is expected to account for the largest share of the global companion diagnostics market by indication. It is also the fastest growing segment owing to the increasing cases of cancer cases across the globe and the rising number of clinical trials targeting cancer biomarkers for lung, breast, and prostate cancers.
Press release : https://www.prnewswire.com/news-releases/companion-diagnostics-market-to-reach-usd-651-billion-by-2022-637833923.html
The key players in the global companion diagnostics market are Roche Diagnostics (Switzerland), Agilent Technologies, Inc. (U.S.), QIAGEN N.V. (Netherlands), and Abbott Laboratories Inc. (U.S.).
Target Audience:
Pharmaceutical and biotechnology companies
Diagnostic manufacturers
Research laboratories and academic institutes
Research and development (R&D) companies
Clinical research organizations (CROs)
Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownload.asp?id=155571681
Scope of the Report:
The research report categorizes the global market into the following segments and subsegments:
Companion Diagnostics Market, by Product & Service
Assays & Reagents
Software & Services
Companion Diagnostics Market, by Indication
Oncology
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Gastric Cancer
Other Types of Cancer
Infectious Diseases
Neurology
Other Indications
*Other indications include cardiovascular diseases, inflammatory diseases, and inherited diseases
Companion Diagnostics Market, by Technology
Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)
In Situ Hybridization (ISH)
Next-generation Sequencing
Other Technologies
*Other technologies include multiplex assay and imaging technology.
Companion Diagnostics Market, by End User
Pharmaceutical and Biopharmaceutical Companies
Reference Lab
Other End User
*Other end users include CROs, physician labs, hospital labs, and academic medical centers
Companion Diagnostics Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
France
Rest of Europe (RoE)
Asia-Pacific
RoW
MarketsandMarkets
Mr. Shelly Singh
1-888-600-6441
sales@marketsandmarkets.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
